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Abstract
Background: A simple technique to measure dynamic hy-
perinflation (DH) in patients with chronic obstructive pulmo-
nary disease (COPD) is the metronome-paced tachypnea 
test (MPT). Earlier studies show conflicting results about the 
accuracy of the MPT compared to cardiopulmonary exercise 
testing (CPET). Objectives: The focus was to investigate the 
diagnostic accuracy of MPT to detect DH in a prospective 
and clinical study. Methods: COPD patients were included; 
all underwent spirometry, CPET, and MPT. DH (ΔIC) was cal-
culated as the difference in % between inspiratory capacity 
(IC) at the start and end of the test divided by IC at the start. 
A subject was identified as a hyperinflator, if ΔIC (% of ICrest) 
was smaller than –10.2 and –11.1% in CPET and MPT, respec-
tively. With these values, sensitivity and specificity were cal-
culated. Bland-Altman plots were made of ΔIC (% of ICrest). 
Results: In the prospective and clinical study, 107 and 48 pa-
tients were included, respectively. Sensitivity of the MPT was 
85% in both studies. The specificities were 33 and 27%, re-
spectively. In the prospective study, B = +2.6%, L = 30.6, and 
–25.6%. In the clinical study, B = +0.8%, L = 31.0, and –29.1%. 
Conclusion: MPT seems to be a good replacement for CPET 
in group studies. The mean amount of DH was not different 
between CPET and MPT. On an individual level, MPT cannot 
be used to identify hyperinflators; it should be kept in mind 
that MPT overdiagnoses DH. The amount of DH should not 
be interchanged between CPET and MPT.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Nowadays, cardiopulmonary exercise testing (CPET) 
is used clinically to quantify dynamic hyperinflation 
(DH). During CPET, DH is measured indirectly by se-
rial measurement of the inspiratory capacity (IC) at the 
start and end of the test. However, it is a rather com- 
plex and time-consuming test. A simpler and already 
used technique is the metronome-paced tachypnea test 
(MPT). The MPT test was first used by Gelb et al. [1], in 
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16 chronic obstructive pulmonary disease (COPD) pa-
tients. Gelb et al. [1] showed that DH with MPT was 
similar to DH with a CPET, if a subject breathed at twice 
the resting respiratory rate for 20 s. Since, the MPT test 
has been used in multiple studies to investigate the re-
sponse to various bronchodilators [1–4], the develop-
ment of DH during exacerbations [5], the role of DH in 
COPD [6], and the development of DH over the course 
of years [7]. Despite its increasing use as a valid mea-
surement tool, only little is known about the accuracy of 
the MPT. Therefore, it is unknown whether the MPT 
test can be used to determine DH in the individual pa-
tient in clinical practice.
Previous research has shown that there are conflict-
ing results regarding the accuracy of the MPT test. Two 
studies exist investigating the accuracy of the MPT test 
based on comparison with CPET. The study by Calli-
garo et al. [3] describes the performance and standard-
ization of MPT. They reported a sensitivity of 90% and 
a specificity of 38%. Lahaije et al. [8] found a better ac-
curacy, with a sensitivity and specificity of 85%. Both 
previously published studies are limited to a small and/
or specific group of COPD patients. In the study by Cal-
ligaro et al. [3], only 24 COPD patients were included, 
from which 23 patients were in stage GOLD II. Lahaije 
et al. [8] included a larger group of COPD patients; i.e., 
60 patients. However, the included patients were no 
good representation of an average COPD population, 
as the they were recruited from a pool of patients who 
were screened for pulmonary rehabilitation. Moreover, 
both studies were prospective and performed in a re-
search setting, suggesting that MPT and CPET were 
performed under strict conditions and with the focus 
on correct execution of both tests. Therefore, the accu-
racy found in both studies may not be applicable to a 
clinical setting.
In this study, the focus was to find a conclusive answer 
considering the diagnostic accuracy of MPT to detect 
DH. In the design of this study, the limitations of both 
studies (Calligaro et al. [3] and Lahaije et al. [8]) were 
considered. This study can be divided into two parts, a 
prospective and retrospective clinical part. In the pro-
spective study, a large group of COPD patients was in-
cluded, and it was ensured that the group is a good repre-
sentation of an average COPD population. In the clinical 
study, the accuracy was studied under less strict condi-
tions. In this way, the accuracy of MPT was determined 
in clinical practice, where the MPT test was used as a stan-
dard lung function test in the diagnostic assessment of 
COPD patients.
Materials and Methods
Subjects
In a single-center prospective cohort study (Trial register: 
NTR4764), patients with a chest-physician-confirmed COPD were 
recruited at the Medical Centre Leeuwarden (MCL), The Nether-
lands. The severity of disease was classified according to the Glob-
al Initiative for Chronic Obstructive Lung Disease (GOLD) stages 
[9]. All patients with COPD who were referred for CPET for the 
rehabilitation, dyspnea analysis, and VO2max measurement, were 
included. Patients were excluded, if they were not able to perform 
CPET or MPT due to, e.g., other comorbidities. All participants 
gave informed consent prior to entering the study. In the clinical 
study, a retrospective study was performed with data of COPD pa-
tients who were analyzed because of dyspnea complaints at the 
Radboud University Medical Center, Nijmegen, The Netherlands. 
Both studies were conducted according to the Declaration of Hel-
sinki. The prospective study (file No. NL50155.099.14/RTPO924) 
was approved by the Research Ethics Committee “Regionale Toet-
singscommissie Patiëntgebonden Onderzoek” (RTPO). The clini-
cal study was approved by the Research Ethics Committee of the 
Radboud University Nijmegen Medical Centre (file No. CMO: 
2018-4357).
The severity of disease was classified according to the GOLD 
stages [9]. For both studies, clinically stable patients were included.
Study Design
All subjects underwent spirometry, CPET, and MPT. Spirom-
etry was performed according to the American Thoracic Society/
European Respiratory Society guidelines for lung function mea-
surements [10]. In both studies, MPT and CPET were performed 
under medication. In the prospective study, all tests were per-
formed on one day. In the clinical study, MPT was not performed 
on the same day as CPET (with a maximal time span between MPT 
and CPET of 3 months).
CPET
All patients performed a symptom-limited incremental exer-
cise test using an electrically braked cycle ergometer (Lode B.V.; 
Lode Excalibur Sport, Groningen, The Netherlands). They wore a 
leakage-free face mask with a turbine flow transducer and a gas 
sampling tube (MCL: ZAN, zan100; Accuramed, Belgium; Rad-
boud University Medical Center: VitalAire Nederland BV, Eind-
hoven, The Netherlands). Measurements were performed accord-
ing to the American Thoracic Society/European Respiratory Soci-
ety guidelines for CPET (2003) [11]. Reference equations for 
calculation of predicted values were those produced by Wasser-
man [12].
DH was determined by measuring changes in the IC. First, pa-
tients were asked to sit upright and relaxed on the bike. Patients 
should have shown at least four consistent end-expiratory levels 
before carrying out an IC maneuver. The mean of three acceptable 
measurements (< 5% or < 100-ml difference) was taken as baseline 
IC (ICrestCPET) [10]. At the moment of maximal exercise, one IC 
was measured (ICCPET).
MPT
Patients were seated, breathing through a mouthpiece connect-
ed to the spirometer (Masterlab PFT; Vitalaire, Germany). After a 
quiet and stable breathing was attained, the mean of three accept-
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able maneuvers (< 10% difference) was used to establish ICrest-
MPT. Thereafter, patients were asked to breathe twice their resting 
breathing rate using a web-based metronome, with equal inspira-
tory and expiratory time. They were instructed to maintain their 
tidal volume the same as at rest. After breathing 20 s, an IC maneu-
ver was performed [1]. The MPT following an IC maneuver was 
repeated three times. A few minutes were taken in between, and 
the next maneuver was performed after recovery to a stable resting 
lung volume. The mean of three acceptable IC maneuvers was IC 
after MPT (ICMPT).
Statistical Analysis
Based on the results of Lahaije et al. [8], a power analysis for 
the prospective study was performed (5,000 Monte Carlo sam-
ples of null and alternative distribution). A difference of 10% be-
tween the ΔIC of both tests was accepted (based on the repeat-
ability coefficient found by Lahaije et al. [8]). With a power of 
80%, a significance of 0.05 (two-paired t test), and a correlation 
of 0.20 (conservative approach), we calculated a sample size of 
110 patients.
Baseline characteristics are described by mean ± standard de-
viation or median ± interquartile range, depending on normality. 
DH (ΔIC) is the difference in % between IC at the start (ICrest-
CPET, ICrestMPT) and end of the test (ICCPET, ICMPT) di-
vided by ICrest (ICrestCPET, ICrestMPT). A more negative val-
ue of ΔIC corresponds with a higher amount of induced DH. ΔIC 
measured with CPET as reference and MPT was compared with 
the Bland-Altman analysis. As cutoff point for DH, the cutoff 
values from the study by Lahaije et al. [8] were used. A subject 
was identified as a hyperinflator, if ΔIC (% of ICrest) was below 
–10.2 and –11.1% in CPET and MPT, respectively. With these 
values, the sensitivity and specificity of MPT relative to the refer-
ence CPET were calculated.
Results
Hundred-seven clinically stable patients with COPD 
(FEV1%pred 53 ± 18) were included in the prospective 
study between August 2014 and August 2016.
In the clinical study, forty-eight clinically stable pa-
tients with COPD (FEV1%pred 53 ± 17) were included 
between October 2014 and April 2018. Both groups con-
sisted of mild-to-very-severe COPD patients (GOLD 
guidelines [13]). The baseline characteristics are present-
ed as mean (standard deviation) in Table 1.
Accuracy
The sensitivity and specificity of the MPT relative to 
CPET was 85 and 33%, respectively. The positive predic-
tive value of the MPT was 84%, and the negative predic-
tive value was 35%. In the clinical study, the sensitivity 
and specificity of the MPT relative to CPET were 85 and 
27%, respectively. The positive predictive value of the 
MPT was 74%, and the negative predictive value was 44%. 
Prospective study
(n = 107)
Clinical study
(n = 48)
Age, years 63.3 (10.6) 61.4 (8.1)
Sex, males/females 66/41 (62 vs. 38%) 21/27 (44 vs. 56%)
BMI 26.1 (5.2) 25.3 (5.6)
FEV1, L 1.58 (0.68) 1.45 (0.46)
FEV1, %pred 53 (18) 50 (14)
FEV1/FVC% 49 (15) 43 (11)
COPD Gold I/II/III/IV 9/51/33/14 1/20/26/1
Values are presented as mean (standard deviation), unless otherwise indicated.
Table 1. Demographics of all subjects for 
both the prospective and clinical study
Table 2. Number of patients per quadrant (prospective study)
CPET+ CPET– Total
MPT+ 73 14 87
MPT– 13 7 20
Total 86 21 107
Table 3. Number of patients per quadrant (clinical study)
CPET+ CPET– Total
MPT+ 29 10 39
MPT– 5 4 9
Total 34 14 48
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See Figure 1a (prospective), 1b (clinical) for quadrant fig-
ures, and Tables 2 and 3 for the number of patients per 
quadrant.
Comparison DH with CPET and MPT
In the prospective study, the mean ΔICMPT (% of 
ICrestMPT) was –23 ± 12% (–0.57 ± 0.36 L), and the 
mean ΔICCPET (% of ICrestCPET) was –21 ± 15% (–0.51 
± 0.41 L). In the clinical study, the mean ΔICMPT (% of 
ICrestMPT) was –19 ± 10% (–0.41 ± 0.23 L), and the 
mean ΔICCPET (% of ICrestCPET) was –19 ± 15.0% 
(–0.49 ± 0.42 L). There is no significant difference in the 
mean ΔICCPET (% of ICrestCPET) and ΔICMPT (% of 
ICrestMPT) between both studies.
In both the prospective and clinical study, there was no 
significant difference between the mean ΔICCPET (% of 
ICrestCPET) and ΔICMPT (% of ICrestMPT) (p = 0.07 
and 0.73, respectively). In Figure 2a and b, the Bland-Alt-
man analysis of both studies can be found. The bias be-
tween ΔICCPET and ΔICMPT was 2.6 and 0.8%, respec-
tively.
Discussion
In this study, the focus was to investigate the diag-
nostic accuracy of MPT to detect DH in two settings. 
First, a prospective study was performed, and second, a 
retrospective database study was performed at the Rad-
boud University Medical Center. The sensitivity of the 
MPT was good; in both studies, 85% of the subjects 
were correctly identified as hyperinflators. However, 
the specificity was low. The mean difference between 
ΔIC (% of ICrest), measured with both methods, was 
small, and in both studies, the limits of agreement were 
wide.
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Fig. 1. Subjects correctly and incorrectly identified by MPT. On the 
x-axis, DH was measured with CPET, and on the y-axis, DH was 
measured with MPT. The lower left quadrant contains the true 
positives, the upper right quadrant the true negatives. The upper 
left quadrant shows false negatives, and the lower right quadrant 
shows false positives. The cutoff value was –10.2% for CPET and 
–11.1% for MPT in a the prospective study and b the clinical study. 
GOLD classification is presented with the following markers: 
GOLD I = filled square, GOLD II = circle, GOLD III = asterisk, 
GOLD IV = filled triangle.
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Accuracy
In both the prospective and clinical study, the sen-
sitivity was 85%. The specificity was 33 and 27%, re-
spectively. From these results, it can be concluded that 
the overall accuracy of MPT is questionable. Especial-
ly, the specificity of MPT is low, which means that 
MPT fails to correctly identify nonhyperinflators. In 
practice, this could lead to overdiagnosis of DH, if 
MPT would replace CPET. However, the sensitivity of 
the MPT is good, which means that the chance is high 
that a subject who shows DH during MPT has DH dur-
ing CPET.
In the study by Lahaije et al. [8], a sensitivity and 
specificity were found of 85 and 85%, respectively. Cal-
ligaro et al. [3] found a sensitivity and specificity of 90 
and 38%, respectively. The sensitivity and specificity in 
our study and in the study by Calligaro et al. [3] are 
comparable. The difference in sensitivity and specific-
ity in the studies by Lahaije et al. [8] and our study 
might be explained by a difference in population. Espe-
cially for CPET-induced DH, a different population can 
have a consequence. In the study by Lahaije et al. [8], 
the thirty-five COPD patients were included at their 
initial screening for pulmonary rehabilitation. They 
concluded that there might have been a selection bias 
because a higher prevalence of DH (in CPET) may be 
expected in patients with COPD referred for rehabilita-
tion. During MPT, the chance of developing DH is 
high, even in healthy subjects [8, 14]. While in CPET, 
the chance of inducing DH is smaller. In our study, the 
population with milder forms of COPD could have in-
troduced more false-positives (i.e., DH in MPT+ and 
DH in CPET–). Moreover, we did not include healthy 
subjects, which was also the case in the study by Calli-
garo et al. [3]. This makes the true-negative group 
smaller, affecting the specificity. This can be supported 
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Fig. 2. Bland-Altman plot comparing the relative CPET-induced 
DH with MPT-induced DH. A positive value on the y-axis means an 
overestimation of DH as measured with MPT. GOLD classification 
is presented with the following markers: GOLD A = filled square, 
GOLD B = circle, GOLD C = asterisk, GOLD D = filled triangle. The 
bias (B) is presented as the solid line; limits of agreement (L) are 
dashed lines. a Prospective study: B = +2.6%; L = 30.6%, and –25.6%. 
b Clinical study: B = +0.8%, L = 31.0, and –29.1%.
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by the findings in the study by Lahaije et al. [8], in which 
a lower specificity (71%) was found in a subanalysis ex-
cluding healthy subjects.
Comparison DH
In the prospective and clinical study, the bias was +2.6 
and +0.8%, a small overestimation of DH with MPT. Lim-
its of agreement were wide: 30.6 and –25.6%, and 31.0 and 
–29.1%, respectively. Lahaije et al. [8] found an overesti-
mation of MPT of 3.0% on CPET, with limits of agree-
ment of ±24%. Calligaro et al. [3] state that MPT overes-
timates DH; the corresponding bias is not given. All stud-
ies show that MPT tends to slightly overestimate DH, 
which is neglectable from a clinical point of view.
One explanation is that MPT- and CPET-induced DH 
are physiologically different. In both the clinical and pro-
spective study, all subjects had to breathe at twice their 
resting frequency during MPT. In the CPET, the respira-
tory frequency is not imposed. Most of the time, the max-
imal respiratory rate in CPET is smaller than in MPT and 
often not equal at the end of the test. In addition, during 
MPT, subjects were encouraged to keep the tidal volume 
equal to the resting tidal volume, while this was not the 
case in CPET. In the study by Cooper et al. [14], it is dem-
onstrated that not only breathing frequency determines 
the amount of DH. The ratio between inspiratory and ex-
piratory time is also an important factor. Moreover, it can 
be hypothesized that tidal volume also determines the in-
duction of DH. Thus, it can be reasoned that DH induced 
by MPT and CPET are physiologically different and not 
comparable. Moreover, it should be kept in mind that the 
MPT has a “subject-specific” protocol (i.e., subject 1 has 
a MPT frequency of 40, while subject 2 has a MPT fre-
quency of 20). This could mean that DH measured with 
MPT is not comparable between subjects.
In addition to the physiological difference of the un-
derlying mechanism, a difference in the measurement 
setup could further increase the difference in the induced 
DH. In CPET, the subject wears a mask while the subject 
breathes through a mouth piece during MPT. During 
CPET, a subject can use the pursed-lip breathing tech-
nique, which could help the patient prevent the induction 
of DH, or at least reduce the amount of DH.
Clinical Implications
Our studies show a nonsignificant difference between 
the mean ΔICCPET and ΔICMPT. Therefore, in a group, 
the mean DH measured with MPT and CPET is inter-
changeable. Together with the studies of Lahaije et al. [8] 
and Calligaro et al. [3], it can be concluded that studies in-
vestigating the effect of therapy on DH [2, 3], the coherence 
of DH with other parameters [15], or the development of 
DH over time in a group with COPD patients [1, 7] can be 
simplified by measuring with MPT instead of using the 
more labor-intensive CPET. On an individual level, MPT 
should be used cautiously to determine, if a subject is a 
(non-) hyperinflator. It should be kept in mind that this 
leads to false-positives (i.e., labelled as a hyperinflator, 
while he/she is not a hyperinflator). In addition, the amount 
of DH (ΔIC [% of ICrest]) is not comparable between the 
two methods for an individual, as the Bland-Altman analy-
sis showed that the difference between ΔICCPET (% of 
ICrest) and ΔICMPT (% of ICrest) varies greatly. DH is 
probably hard to express in numbers and is dependent on 
activity/test, so it should be described as present or absent.
Limitations
There remains uncertainty on the validity of the mea-
surement of DH with the reference method CPET. CPET 
is a time-consuming test, and effort is needed from both 
the patient and physician. The instructions might be 
harder to follow during CPET than MPT. However, it is 
beyond the scope of this article to elaborate further on the 
limitations of CPET.
In the clinical study, the tests were not necessarily car-
ried out on the same day. The results of the study by 
Hannink et al. [7] suggest that DH changes over time in 
patients with COPD. Therefore, DH measured with 
CPET and MPT can be different. This would suggest that 
the reliability of the outcomes is less accurate than when 
CPET and MPT measurements take place on the same 
day. However, it is reasoned that the effect of measure-
ment of DH on different days is neglectable. Indeed, there 
was no difference in sensitivity (85%) between both the 
prospective and clinical study, and the difference in spec-
ificity (33 and 27%) is minimal.
Another limitation might be that we did not use the 
optimal cutoff value to determine the accuracy of MPT. 
For example, another cutoff value is used in the study by 
Calligaro et al. [3]. DH was considered present, if the dif-
ference in IC was more than 1.96 SD below ICrest. We 
used the cutoff values of Lahaije et al. [8] to prevent even 
more cutoff values to appear in the literature. The cutoff 
values were 10.2 and 11.1% for the CPET and MPT test, 
respectively, which were based on ROC analysis. It is hy-
pothesized that this value is close to the true optimal cut-
off value, as these values were close to the repeatability 
coefficient of the IC in rest.
In conclusion, MPT seems to be a good replacement for 
CPET in group studies. The mean amount of DH on group 
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basis does not differ between CPET and MPT. On an indi-
vidual level and for diagnostic use, MPT should be used 
with caution to identify hyperinflators; it should be kept in 
mind that MPT overdiagnoses DH. The amount of DH 
should not be interchanged between CPET and MPT. To 
increase the clinical value of the MPT, future studies should 
focus on finding the clinical accuracy of the MPT in an in-
dividual based on pre- and post-treatment measurements 
(e.g., rehabilitation or medical intervention). Moreover, 
more research on the standardization of the MPT protocol 
(e.g., tidal volume, breathing frequency) could be impor-
tant to increase its clinical value.
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